|
CN102186481A
|
|
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
|
EP2252304A2
|
|
Platinum aggregates and process for producing the same
|
|
CN101917972A
|
|
Liposomal vancomycin formulations
|
|
US2009130194A1
|
|
Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
|
|
WO2008137917A1
|
|
Method of treating bacterial infections with antibacterial formulations
|
|
WO2008137717A1
|
|
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
|
WO2008039987A2
|
|
Methods of treating pulmonary distress
|
|
WO2008039989A2
|
|
Formulations of dnase and methods of use thereof
|
|
WO2007064658A2
|
|
Safe and effective methods of administering therapeutic agents
|
|
US2007065522A1
|
|
Administration of high potency platinum compound formulations by inhalation
|
|
US2007077290A1
|
|
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
|
US2006159712A1
|
|
Lipid particles comprising bioactive agents, methods of preparing and uses thereof
|
|
EP1811963A2
|
|
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
|
CN101056620A
|
|
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
|
AU2005227364A1
|
|
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
|
US2006073198A1
|
|
Sustained release of antiinfectives
|
|
CN101001633A
|
|
Treatment of lung diseases and pre-lung disease conditions
|
|
CN1976711A
|
|
Administration of cisplatin by inhalation
|
|
CN1747738A
|
|
Sustained release of antifectives
|
|
MXPA05001312A
|
|
Platinum aggregates and process for producing the same.
|
